Contact: N/A
Email: N/A
Background: The growing incidence of Inflammatory Bowel Disease in Colorado and the surrounding border states is a significant cause for concern for readmissions and high costs to treat ($12,679-$18,739 annually per patient). Betterpath is building a tool that takes an individual patient’s medical data and compares it to the larger patient cohort in order to compare and contrast different treatment regimens based on cost and effectiveness. To do so, Betterpath needs to analyze large institutional datasets that contain information on costs, diagnosis, treatments and procedures.
Goal: Develop metrics around medication effectiveness and preventive approaches that will drastically reduce the overall medical costs incurred by IBD patients.
Data Analyzed: All commercial claims data associated with specific IBD procedural codes.
Results: In progress.